logo

For the Inventor, By the Inventor

Toronto, Canada

Affinium Pharmaceuticals, Inc.


USPTO Granted Patents = 33

% Expired Patents = 60.6


Forward Citations = 410

Loading Chart...
Loading Chart...

62 inventors (with patents filed for the assignee):

goldMedal Mark Andrew Seefeld (15 out of 37 patents)

silverMedal Kenneth Allen Newlander (15 out of 54 patents)

bronzeMedal William Henry Miller (14 out of 73 patents)

4.  Irene Nijole Uzinskas (10 out of 16 patents)

5.  Dalia R Jakas (9 out of 12 patents)

6.  Walter E Dewolf, Jr (7 out of 7 patents)

7.  David John Payne (6 out of 21 patents)

8.  Judd Berman (4 out of 7 patents)

9.  Jailall Ramnauth (4 out of 17 patents)

10.  Walter J Burgess (4 out of 4 patents)

11.  Joshua M West (4 out of 4 patents)

12.  Nicola Gail Wallis (4 out of 59 patents)

13.  William F Huffman (4 out of 47 patents)

14.  Peter Brent Sampson (3 out of 33 patents)

15.  Donald E Awrey (3 out of 3 patents)


Core Competencies:
Fab I Inhibitors
Acrylamide Derivatives
Bioactive Agents
Heterocyclic Compounds
FabK Variant
Antibacterial Compounds
Polymorphs
Prodrugs
High Throughput Screening
Fatty Acid Biosynthesis
Protein-Protein Interactions
Imidazoles

33 patents:

1. 8450307 - Therapeutic agents, and methods of making and using the same (2013-05-28),
2. 8318720 - Acrylamide derivatives as Fab I inhibitors (2012-11-27),
3. 8263613 - Salts, prodrugs and polymorphs of fab I inhibitors (2012-09-11),
4. 8173646 - FAB I inhibitors (2012-05-08),
5. 8153652 - Fab I inhibitors (2012-04-10),
6. 7879872 - Compositions comprising multiple bioactive agents, and methods of using the same (2011-02-01),
7. 7799547 - [object Object] (2010-09-21),
8. 7790716 - Fab I inhibitors (2010-09-07),
9. 7790709 - Heterocyclic compounds, methods of making them and their use in therapy (2010-09-07),
10. 7741339 - Fab I inhibitors (2010-06-22),
11. 7601526 - [object Object] (2009-10-13),
12. 7557125 - Fab I inhibitors (2009-07-07),
13. 7524843 - Fab I inhibitors (2009-04-28),
14. 7422749 - Compounds (2008-09-09),
15. 7250424 - Fab I inhibitors (2007-07-31),
Company Overview
Affinium Pharmaceuticals, Inc. is a biopharmaceutical company based in Toronto, Canada, focused on developing innovative therapies for serious diseases. The company specializes in the research and development of novel drug candidates, particularly in the fields of oncology and infectious diseases. Affinium leverages advanced scientific expertise and cutting-edge technology to address unmet medical needs, aiming to improve patient outcomes through targeted treatment approaches.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

33 Patents

#41 in Toronto

#406 in Canada

#20,147 in the World

Toronto, CA
Toronto, Canada

Affinium Pharmaceuticals, Inc.

Forward Citations = 410

62 inventors:

goldMedal Mark Andrew Seefeld (15 out of 37 patents)

silverMedal Kenneth Allen Newlander (15 out of 54 patents)

bronzeMedal William Henry Miller (14 out of 73 patents)

4.  Irene Nijole Uzinskas (10 out of 16 patents)

5.  Dalia R Jakas (9 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Affinium Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/affinium-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…